NO20005755D0 - Kombinasjonsterapi omfattende ribavirin og interferon <alfa> i antivirusbehandling av naive pasienter med kronisk hepatitt C- infeksjon - Google Patents

Kombinasjonsterapi omfattende ribavirin og interferon <alfa> i antivirusbehandling av naive pasienter med kronisk hepatitt C- infeksjon

Info

Publication number
NO20005755D0
NO20005755D0 NO20005755A NO20005755A NO20005755D0 NO 20005755 D0 NO20005755 D0 NO 20005755D0 NO 20005755 A NO20005755 A NO 20005755A NO 20005755 A NO20005755 A NO 20005755A NO 20005755 D0 NO20005755 D0 NO 20005755D0
Authority
NO
Norway
Prior art keywords
ribavirin
alfa
interferon
infection
combination therapy
Prior art date
Application number
NO20005755A
Other languages
English (en)
Other versions
NO330715B1 (no
NO20005755L (no
Inventor
Janice K Albrecht
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20005755(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20005755D0 publication Critical patent/NO20005755D0/no
Publication of NO20005755L publication Critical patent/NO20005755L/no
Publication of NO330715B1 publication Critical patent/NO330715B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20005755A 1998-05-15 2000-11-14 Anvendelse av ribavirin og interferon-alfa i kombinasjon for fremstilling av et farmasoytisk preparat for behandling av kronisk hepatitt-C-infeksjon hos pasienter som har HCV-genotype-1 med en virusmengde over 2 millioner kopier per ml serum. NO330715B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956698A 1998-05-15 1998-05-15
PCT/US1999/007037 WO1999059621A1 (en) 1998-05-15 1999-05-13 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (3)

Publication Number Publication Date
NO20005755D0 true NO20005755D0 (no) 2000-11-14
NO20005755L NO20005755L (no) 2001-01-12
NO330715B1 NO330715B1 (no) 2011-06-20

Family

ID=22151354

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005755A NO330715B1 (no) 1998-05-15 2000-11-14 Anvendelse av ribavirin og interferon-alfa i kombinasjon for fremstilling av et farmasoytisk preparat for behandling av kronisk hepatitt-C-infeksjon hos pasienter som har HCV-genotype-1 med en virusmengde over 2 millioner kopier per ml serum.

Country Status (22)

Country Link
EP (3) EP2305287A1 (no)
JP (2) JP5281726B2 (no)
KR (1) KR100694345B1 (no)
CN (1) CN1230198C (no)
AR (1) AR019551A1 (no)
AT (1) ATE216591T1 (no)
AU (2) AU766597B2 (no)
BR (1) BR9910505A (no)
CA (1) CA2331823A1 (no)
CZ (1) CZ300540B6 (no)
DE (1) DE69901321T2 (no)
DK (1) DK0956861T3 (no)
ES (1) ES2172288T3 (no)
HU (1) HU230432B1 (no)
IL (3) IL139220A0 (no)
MY (1) MY129244A (no)
NO (1) NO330715B1 (no)
NZ (1) NZ507621A (no)
PT (1) PT956861E (no)
SK (1) SK288038B6 (no)
TW (1) TWI277424B (no)
WO (1) WO1999059621A1 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2354536A1 (en) * 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
CZ20022112A3 (cs) * 1999-12-23 2003-05-14 Ribapharm Inc. Prostředky a způsoby, týkající se L-nukleosidů, L-nukleotidů, a jejich analog
JP4536194B2 (ja) * 2000-02-17 2010-09-01 大日本住友製薬株式会社 安定な注射用製剤
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
AU2002213343A1 (en) * 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003247084B9 (en) 2002-06-28 2018-07-26 Centre National De La Recherche Scientifique Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
AU2003298658A1 (en) 2002-11-15 2004-06-15 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
JP2006524227A (ja) * 2003-03-28 2006-10-26 ファーマセット，インク． フラビウイルス科ウイルス感染の治療のための化合物
CA2520148A1 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
WO2004091653A1 (en) * 2003-04-17 2004-10-28 Ares Trading S.A. Interferon beta in severe acute respiratory syndrome (sars)
RU2358979C2 (ru) 2003-05-30 2009-06-20 Фармассет, Инк. Модифицированные фторированные аналоги нуклеозида
WO2004108151A1 (en) * 2003-06-09 2004-12-16 Genome Institute Of Singapore Inhibition of sars coronavirus infection with clinically approved antiviral drugs
CN1835765A (zh) * 2003-08-13 2006-09-20 霍华德·J·史密斯及同仁控股有限公司 治疗病毒感染的方法
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
ES2725457T3 (es) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparación de ribofuranosil pirimidinas y purinas 2'fluoro-2'-alquil-sustituidas u otras opcionalmente sustituidas y sus derivados
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
MX2008008723A (es) * 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2694440A1 (en) 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
RU2369403C1 (ru) * 2008-05-22 2009-10-10 Сергей Юрьевич Родионов Способ лечения хронических вирусных гепатитов
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
WO2012045704A1 (en) * 2010-10-05 2012-04-12 Novartis Ag New treatments of hepatitis c virus infection
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
KR102198749B1 (ko) * 2011-03-02 2021-01-06 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ES2214551T3 (es) * 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
CA2298543A1 (en) 1997-08-13 1999-02-25 James Barry Loading and release of water-insoluble drugs
PT903148E (pt) * 1997-09-21 2002-02-28 Schering Corp Terapia de combinacao para a erradicacao de rna de hcv detectavel em doentes tendo infeccao cronica pelo virus da hepatite c

Also Published As

Publication number Publication date
IL207259A0 (en) 2010-12-30
CZ300540B6 (cs) 2009-06-10
HU230432B1 (hu) 2016-06-28
ATE216591T1 (de) 2002-05-15
IL207259A (en) 2016-08-31
DE69901321D1 (de) 2002-05-29
KR100694345B1 (ko) 2007-03-12
AU2005220271B9 (en) 2010-12-09
CN1309568A (zh) 2001-08-22
DE69901321T2 (de) 2002-12-12
HUP0103423A3 (en) 2003-11-28
SK17102000A3 (sk) 2001-05-10
EP0956861B1 (en) 2002-04-24
AU766597B2 (en) 2003-10-16
EP2305287A1 (en) 2011-04-06
CN1230198C (zh) 2005-12-07
NZ507621A (en) 2002-11-26
IL139220A (en) 2013-02-28
WO1999059621A1 (en) 1999-11-25
NO330715B1 (no) 2011-06-20
EP1213029A1 (en) 2002-06-12
AU2005220271B2 (en) 2005-11-03
AU3860099A (en) 1999-12-06
PT956861E (pt) 2002-08-30
JP2011173898A (ja) 2011-09-08
AR019551A1 (es) 2002-02-27
CZ20004177A3 (cs) 2001-04-11
CA2331823A1 (en) 1999-11-25
IL139220A0 (en) 2001-11-25
MY129244A (en) 2007-03-30
HK1021131A1 (en) 2000-06-02
AU2005220271B8 (en) 2010-11-18
DK0956861T3 (da) 2002-07-01
JP2002515453A (ja) 2002-05-28
SK288038B6 (en) 2013-01-02
BR9910505A (pt) 2001-01-02
JP5281726B2 (ja) 2013-09-04
AU2005220271A1 (en) 2005-11-03
NO20005755L (no) 2001-01-12
TWI277424B (en) 2007-04-01
KR20010043624A (ko) 2001-05-25
HUP0103423A2 (hu) 2002-01-28
ES2172288T3 (es) 2002-09-16
EP0956861A1 (en) 1999-11-17

Similar Documents

Publication Publication Date Title
IL207259A0 (en) Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
NO20006178D0 (no) Anvendelse av PEG-IFN-&lt;alfa&gt; og ribavirin for behandling av kronisk hepatitt C
ATE230999T1 (de) Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infection
NO20031742L (no) HCV-kombinasjonsterapi med ribavirin og pegylert interferon alfa
NO995263L (no) Konjugater av polyetylenglykol og interferon-&lt;alfa&gt; for terapi av infeksjoner
NO20023043L (no) Substituerte oksazolidinoner og deres anvendelse innenfor feltet blodkoagulasjon
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
TR200101085T2 (tr) Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA&#39;nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
NO996265L (no) Behandling av diabetes med rosiglitazon og insulin
KR960702315A (ko) 혈관 차단 치료에서의 헤모글로빈의 치료적 용도 (Therapeutic Use of Hemoglobin in the Treatment of Blood Vessel Blockage)
FI973185A0 (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
NO20041685L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon hos pasienter med manglende behandlingsrespons
NO20024325D0 (no) Rensede hepatitt C-viruskappeproteiner for diagnostisk og terapeutisk anvendelse
WO2004006843A3 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
DK0859630T3 (da) Kombination af termozolomid og alfa-IFN til behandling af fremskreden cancer
IS5778A (is) Stökkbrigði af mennskri lifrarbólgu B veiru og notkun hennar
NO20026000L (no) Behandling og forebyggelse av hjertelidelser forbundet med insulinresistens
SI1311279T1 (sl) Zdravljenje hepatitisa c s timozinom, interferonom in ribavirinom
GB9621866D0 (en) Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of hepatitis B virus infection and leprosy

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MK1K Patent expired